Summary
RU51599 is an arginine vasopressin (AVP) release inhibitor and a selective kappa opioid agonist which has a pure water diuresis effect without associated electrolyte excretion. The effect of RU51599 on brain oedema following transient forebrain ischaemia in rats was examined. Under microscopy, the visible vertebral arteries at the second vertebra could be easily electrocauterized and completely cut by microscissors to yield complete cessation of circulation of both vertebral arteries. Transient forebrain ischaemia was induced by this improved highly reproducible technique of four-vessel occlusion model. Forty-three male Wistar rats were separated into six groups; saline-treated (1 ml/kg) normal rats (n=10), RU51599-treated (1 mg/kg) normal rats (n=4), saline-treated (1 ml/kg) rats with complete occlusion of both vertebral arteries (n=5), RU51599-treated (1 mg/kg) rats with complete occlusion of both vertebral arteries (n=5), saline-treated (1 ml/kg) rats with both complete occlusion of both vertebral arteries and carotid occlusion bilaterally during 45 minutes followed by 60 minutes of reperfusion (n=11), RU51599-treated (1 mg/kg) rats with both complete occlusion of both vertebral arteries and carotid occlusion bilaterally during 45 minutes followed by 60 minutes of reperfusion (n=8). The brain water content was determined by the dry-wet weight method. Cerebral blood flow was monitored during ischaemia and reperfusion was performed by laser Doppler flowmetry to make sure to obtain reversible forebrain ischaemia. Effects of RU51599 on concentration of glutamate released from the hippocampal CA1 of rats subjected to 5 minutes four-vessel occlusion and 60 minutes of reperfusion were also investigated by the microdialysis method. This modified four-vessel occlusion method produced reversible forebrain ischaemia with a high level of success. Bilateral carotid occlusion followed by 60 minutes reperfusion caused a significant increase in brain water content (P<0.01), which was significantly attenuated by RU51599 (P<0.01). These findings indicate that the AVP-release inhibitor RU51599 reduced brain oedema following transient forebrain ischaemia in rats.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Baskin DS, Hosobuchi Y (1981) Naloxone reversal of ischaemic neurological deficits in man. Lancet 2: 272–275
Baskin DS, Widmayer MA, Browning JL, Heizer ML, Schmidt WK (1994) Evaluation of delayed treatment of focal cerebral ischemia with three selective κ-opioid agonists in cats. Stroke 25: 2047–2054
DeCoster MA, Conover JR, Hunter JC, Tortella FC (1994) The neuroprotective κ-opioid CI-977 alters glutamate-induced calcium signaling in vitro. Neuroreport 5: 2305–2310
Dickinson LD, Betz AL (1992) Attenuated development of ischemic brain edema in vasopressin-deficient rats. J Cereb Blood Flow Metab 12: 681–690
Dóczi T, László FA, Szerdahelyi P, Joó F (1984) Involvement of vasopressin in brain edema formation; further evidence obtained from the Brattleboro diabetes insipidus rat with experimental subarachnoid hemorrhage. Neurosurgery 14: 436–441
Dóczi TP, Joó F, Balás I (1995) Atrial natriuretic peptide (ANP) attenuates brain edema accompanying experimental subarachnoid haemorrhage. Acta Neurochir (Wien) 132: 87–91
Faden AI (1986) Neuropeptides and central nervous system injury. Clinical implications. Arch Neurol 43: 501–504
Faraci FM, Mayhan WG, Farrell WJ, Heistad DD (1988) Humoral regulation of blood flow to choroid plexus: Role of arginine vasopressin. Circ Res 63: 373–379
Fried RL, Nowak TS (1987) Opioid peptide levels in gerbil brain after transient ischemia: Lasting depletion of hippocampal dynorphin. Stroke 18: 765–770
Furui T (1993) Potential protection by a specific kappa-opiate agonist U-50488H agonist membrane failure in acute ischemic brain. Neuro Med Clir (Tokyo) 33: 133–138
Gannon RL, Terrian DM (1992) Kappa opioid agonists inhibits transmitter release from guinea pig hippocampal mossy fiber synaptosomes. Neurochem Res 17: 741–747
Gannon RL, Terrian DM (1991) U-50488H inhibits dynorphin and glutamate release from guinea pig hippocampal mossy fiber terminals. Brain Res 548: 242–247
Graham SH, Chen J, Sharp FR, Simon RP (1993) Limiting ischemic injury by inhibition of excitory amino acid release. J Cereb Blood Flow Metab 13: 88–97
Hall ED, Pazara KE (1988) Quantitative analysis of effects of κ-opioid agonists on postischemic hippocampal CA1 neuronal necrosis ingerbils. Stroke 19: 1008–1012
Hamon G, Fortin M, Le Martret O, Jouquey S, Vincent JC, Bichet DG (1994) Pharmacological profile of niravoline, a new aquaretie compound. J Am Soc Nephrol 5: 272
Hayward NJ, Hitchcott PK, McKnight AT, Woodruff GN (1993) Effects of enadoline on ischaemic-induced glutamate release. Br J Pharmacol 110: 62
Hosobuchi Y, Baskin DS, Woo SK (1982) Reversal of induced ischemic neurologic deficit in gerbils by the opiate antagonist naloxone. Science 215: 69–71
Hudson CJ, Van Voigtlander PF, Althaus JS, Scherch HM, Means ED (1991) The kappa opioid-related anticonvulsants U50488H and U-54494 A attenuate N methyl-D-aspartate induced brain injury in the neonatal rat. Brain Res 564: 261–267
Ikeda Y, Teramoto A, Nakagawa Y, Ishibashi Y, Yoshii T (1997) Attenuation of cryogenic induced brain edema by arginine vasopressin release inhibitor RU51599. Acta Neurochir (Wien) 139(12): 1173–1180
Isotani E, Suzuki R, Tomita K, Hokari M, Monma S, Marumo F, Hirakawa K (1994) Alteration in plasma concentration of natriuretic peptides and antidiuretic hormone after subarachnoid hemorrhage. Stroke 25: 2198–2203
Kusumoto K, Mackay KB, McCulloch J (1992) The effect of the kappa-opioid receptor agonist CI-977 in a rat of focal cerebral ischaemia. Brain Res 576: 147–151
Lambert PD, Woodruff GN, Hughes J, Hunter JC (1991) Inhibition of L-glutamate release: A possible mechanism of action for the neuroprotective effects of the κ-selective agonist CI-977. Mol Neuropharmacol 1: 77–82
László FA, Varga C, Dóczi T (1995) Cerebral oedema after subarachnoid haemorrhage. Pathogenetic significance of vasopressin. Acta Neurochir (Wien) 133: 122–133
MacKay KB, Patel TR, Galbraith SL, Woodruff GN, McCulloch J (1996) The relationship between glutamate release and cerebral blood flow after cerebral ischaemia in the cat: Effect of pretreatment with enadoline (a kappa receptor agonist). Brain Res 712: 329–334
Millan MH, Chapman AG, Meldrum BS (1995) Dual inhibitory action of enadoline (CI-977) on release of amino acids in the rat hippocampus. Eur J Pharmacol 279: 75–81
Nagao S, Kagawa M, Bemana I, Kuniyoshi T, Ogawa T, Honma Y, Kuyama H (1994) Treatment of vasogenic brain edema with arginine vasopressin receptor antagonist — an experimental study. Acta Neurochir [Suppl] 60: 502–504
Oiso Y, Iwasaki Y, Kondo K, Takatsuki K, Tomita A (1988) Effect of the opioid kappa-receptor agonist U50488H on the secretion of arginine vasopressin. Neuroendocrinology 48: 658–662
Pinnock RD (1992) A highly selective κ-opioid receptor agonists, CI-979, reduces excitatory synaptic potentials in the rat locus coeruleus in vitro. Neuroscience 47: 87–94
Pulsinelli WA, Brierley JB (1979) A new model of bilateral hemispheric ischemia in the unanesthetized rat. Stroke 10: 267–272
Pulsinelli WA, Brierley JB, Plum F (1982) Temporal profile of neuronal damage in a model of transient forebrain ischemia. Ann Neurol 11: 491–498
Raichle ME, Grubb RL (1978) Regulation of brain water permeability by centrally-released vasopressin. Brain Res 143: 191–194
Reeder RF, Nattie EE, North WG (1986) Effect of vasopressin on cold-induced brain edema. J Neurosurg 64: 941–950
Rosenberg GA, Scremin O, Estrada E, Kyner WT (1992) Arginine vasopressin V1-antagonist and atrial natriuretic peptide reduce hemorrhagic brain edema in rats. Stroke 23: 1767–1774
Silvia RC, Slizgi GR, Ludens JH, Tang AH (1987) Protection from ischemia-induced cerebral edema in the rat by U-50488H, a kappa opioid receptor agonist. Brain Res 403: 52–57
Sorensen PS, Gjerris A, Hammer M (1985) Cerebrospinal fluid vasopressin in neurological and psychiatric disorders. J Neurol Neurosurg Psychiatry 48: 50–57
Sugio K, Horigome N, Sakaguchi T, Goto M (1988) A model of bilateral hemispheric ischemia-modified four-vessel occlusion in rats (letter). Stroke 19: 922
Tang AH (1985) Protection from cerebral ischemia by U-50448, a specific kappa opioid analgesic agent. Life Sci 37: 1475–1482
Toda S, Ikeda Y, Nakazawa S (1995) Improvement of highly reproducible technique of four-vessel occlusion model and its study on metabolic changes of cerebral reperfusion in rats. No To Shinkei 47: 369–375
Tortella FC, DeCoster MA (1994) Kappa opioids: Therapeutic considerations in epilepsy and CSN injury. Clin Neuropharmacol 17: 403–416
Tossman U, Eriksson S, Delin A, Hagenfeldt L, Law D, Ungerstedt U (1983) Brain amino acids measured by intracerebral dialysis in portacaval shunted animals. J Neurochem 41: 1046–1051
Von Voigtlander PF, Hall ED, Ochoa MC, Lewis RA, Triezenberg HJ (1987) U-54494A: A unique anticonvulsant related to kappa opioid agonists. J Pharmacol Exp Ther 243: 542–547
Von Voigtlander PF, Lahti RA, Ludens JH (1983) U-50488H: a selective and structurally novel non-mu(kappa) opioid agonist. J Pharmacol Exp Ther 224: 7–12
Xiang JZ, Admson P, Brammer MJ, Campbell IC (1990) The κ-opiate agonist U50488H decreases the entry of45Ca into rat cortical synaptosomes by inhibiting N- but not L-type calcium channels. Neuropharmacology 29: 439–444
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ikeda, Y., Toda, S., Kawamoto, T. et al. Arginine vasopressin release inhibitor RU51599 attenuates brian oedema following transient forebrain ischaemia in rats. Acta neurochir 139, 1166–1172 (1997). https://doi.org/10.1007/BF01410978
Issue Date:
DOI: https://doi.org/10.1007/BF01410978